Our findings unveil a novel therapeutic trajectory that harnesses a single microbial metabolite to activate PPARα-mediated tissue repair/renewal pathways across the gut-liver axis, offering a promising biologic therapeutic for treatment of metabolic and inflammatory liver diseases. This evidence concerns the gene PPARA and liver disorder.